Navigation Links
Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Development Program
Date:5/12/2009

effective, that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, that clinical studies even if successful will lead to product advancement or partnering, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that FDA, CE Mark or other regulatory clearances or UL or other certifications, or partnering or other distribution agreements or other commercialization efforts will be successful or will effectively accelerate the business or market, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population, or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and therapeutic hypothermia devices and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our ability to successfully accelerate the commercialization of our therapeutic hypothermia devices and launch new devices within the timeframes contemplated, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exch
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
10. Cardium Launches New AWARE Clinical Study Website
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group finds that the vascular ... Russia , India and ... 2013, roughly equal to the size of the United ... market will experience much faster growth as a result of strong ... Other key findings from Decision Resources Group,s coverage of the ...
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized and ... 29-30 in San Francisco, CA. This year’s conference brings ... and clinicians focused on addressing and solving the significant ... twelve years since the sequencing of the human genome, ... pharmacogenetic information in the label and molecular diagnostics have ...
(Date:8/20/2014)... , Aug. 20, 2014 /PRNewswire-iReach/ -- A ... transformative collaboration between the school,s bioengineering department and ... of the Intel® Software Academic Program, UCSD,s research ... and the human body.  Photo ... study exhibits the work of Dr. Todd ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 WriteResult®, a ... today that it has expanded its myPROpad™ ePRO tablet ... EQ-5D-5L, one of the most widely used and ... general health status. The EQ-5D is used during clinical ... a measure that can be used to demonstrate Health-Related ...
Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 36th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2EQ-5D™ Assessment Now Available for iPad 2
... hasn't felt a down economy at all. PHC Consulting is focused ... (laboratory clinical and research, physician call points, medical devices, pharmaceutical, etc). ... attributes that growth to a strong web presence. , ... ...
... BioTime’s wholly-owned subsidiary Embryome Sciences, Inc., have ... International Stem Cell Corporation (OTCBB:ISCO) through its ... jointly produce and distribute hundreds of new ... along with corresponding data and reagents. The ...
... /PRNewswire-FirstCall/ - Quest PharmaTech Inc.,(TSX-V: QPT), ("Quest" or ... I/II clinical study designed to investigate appropriate,treatment parameters ... for hair removal applications. The interim results represent ... targeted 100-patient clinical,trial., "The Phase I/II interim ...
Cached Biology Technology:Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point 2 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 2 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 3 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 4 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 5Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal 2Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal 3
(Date:8/21/2014)... the Fram Strait is a key region in the global ... Greenland and Svalbard warm Atlantic water flows to the north ... Arctic water masses and sea ice push their way out ... of the Atlantic water cools here on its way to ... the water caused in this manner drives the global band ...
(Date:8/21/2014)... feeding tube connectors, designed by an international standards process, ... , According to an invited review published in the ... ( NCP ), the official journal of the American ... connectors will greatly reduce the occurrence of misconnection that ... Small-bore connectors, which are used to join medical devices, ...
(Date:8/21/2014)... Acute pancreatitis involves the pancreas digesting itself resulting in ... in the UK around 20,000 patients are diagnosed with ... immediate cure and treatment is restricted to intravenous fluid ... the Faculty of Life Sciences, who led the research, ... reflux from gall stones and excessive alcohol intake combined ...
Breaking Biology News(10 mins):Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3New feeding tube connectors will improve patient safety 2Insulin offers new hope for the treatment of acute pancreatitis 2
... creating a better way to see molecules at work in ... Learning and Memory and the MIT Department of Chemistry are ... also help further understanding of how synapses go awry in ... study will appear in the Oct. 7 issue of ...
... survival rates. Yet, one of the deadliest cancers in ... detect in its early stages. Now, researchers have ... shining diffuse light on cells swabbed from patients, cheeks. ... partial wave spectroscopic (PWS) microscopy--was able to differentiate individuals ...
... make life tougher for farmers and ranchers who live in ... why not turn the plants into fuel and make some ... alone could supply biomass far into the future, according to ... to fuel is an intriguing idea that,s being investigated by ...
Cached Biology News:MIT researchers develop a better way to see molecules at work in living brain cells 2Cheek swab may detect lung cancer 2Cheek swab may detect lung cancer 3Montana State, partners in 6 states consider converting invasive plants to fuel 2Montana State, partners in 6 states consider converting invasive plants to fuel 3Montana State, partners in 6 states consider converting invasive plants to fuel 4
... through the extracellular matrix (ECM) is an ... cells initiate invasion by adhering to and ... Proteolytic enzymes, such as MMP collagenases, dissolve ... membrane) surrounding the blood vessels to allow ...
... The InnoCyte Laminin-Based 96-well Cell Invasion ... capacity of cells using laminin as a ... potential anti-metastatic agents in vitro in a ... pore size is appropriate for all types ...
... kit allows for quick and reproducible immunoprecipitation (IP) ... system is more reproducible than regular IPs, which ... A/G agarose without disrupting the agarose bed. The ... Release is reversible, and elution of the immune ...
... are designed for the study of protein:protein ... method. Proteins that interact with GST•Tag™, ... are copurified using affinity resins for the ... a spin filter. The complexes are eluted ...
Biology Products: